Tafasitamab

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Tafasitamab, Novartis, Operating cost, Sale, G&A, Asset, Trial of the century, Marketing, European Medicines Agency, Ruxolitinib, Investment, FDA, Food, Cryptocurrency

Cost of Sales: For the full year 2023, cost of sales were € 58.4 million compared to € 48.6 million in 2022.

Key Points: 
  • Cost of Sales: For the full year 2023, cost of sales were € 58.4 million compared to € 48.6 million in 2022.
  • R&D Expenses: For the full year 2023, R&D expenses were € 283.6 million compared to € 297.8 million in 2022.
  • SG&A Expenses: Selling expenses for the full year 2023 were € 81.4 million compared to € 92.4 million in 2022.
  • MorphoSys Group Key Figures (IFRS, end of financial year: December 31, 2023)

EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Retrieved on: 
Tuesday, February 6, 2024
Slate, Partnership, Supervisory board, Centerview Partners, Immediate, Novartis, Tender offer, Tafasitamab, Purchasing, EZH2, Ruxolitinib, Patient, BET, Workforce, GMT, EZH1, Federal Financial Supervisory Authority, Disease, Acquisition, AG, EST, Business analyst, Webcast, Cancer, Schedule, Pharmaceutical industry

Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).

Key Points: 
  • Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).
  • “Novartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.
  • Novartis intends to offer MorphoSys’ shareholders € 68.00 per share in cash, for a total equity value of € 2.7 billion.
  • Creates New Opportunities for MorphoSys’ Colleagues: The agreement between Novartis and MorphoSys includes employee commitments.

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MorphoSys, DLBCL, FC, Tafasitamab, Immunotherapy, Pharmaceutical industry

Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).

Key Points: 
  • Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).
  • “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialization, allowing us to realize significant operating efficiencies and cost synergies,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • In the previous agreement , MorphoSys and Incyte were collaborating and sharing costs for the clinical development and commercialization of tafasitamab in the U.S.; Incyte had exclusive rights outside of the U.S.
  • Under the terms of the new agreement, MorphoSys will receive a payment of $25 million from Incyte and Incyte will gain global development and commercialization rights for tafasitamab.

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, ASCT, Patient, Incidence, European Medicines Agency, Tafasitamab, HKEX, EMA, Immunotherapy, Food, DLBCL, FDA, Lenalidomide, BLA, Marketing, National Medical Products Administration, NHL, NMPA, Pharmaceutical industry

Through this program, the first prescription of tafasitamab in combination with lenalidomide was filled today at the Guangdong Clifford Hospital for an eligible DLBCL patient.

Key Points: 
  • Through this program, the first prescription of tafasitamab in combination with lenalidomide was filled today at the Guangdong Clifford Hospital for an eligible DLBCL patient.
  • The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been approved by regulatory authorities for marketing in Hong Kong or Macao.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “We are pleased to provide eligible patients access to tafasitamab in the Greater Bay Area.
  • DLBCL is the most common type of non-Hodgkin lymphoma (NHL), and its incidence accounts for 31% to 34% of NHL globally.

MONJUVI (tafasitamab-cxix) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Pharmaceutical, Health, Oncology, Health Canada, Research, Immune system, Lenalidomide, European Commission, MHRA, Clinical trial, Civil service commission, Tafasitamab, CD19, ADCC, SWOT, EU4, ADCP, Fine chemical, Vaccine, Pharmaceutical industry, Risk management, DLBCL

This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the MONJUVI market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to MONJUVI for DLBCL?

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Health, Pharmaceutical, Research, Antibody, Immune system, Non-Hodgkin lymphoma, Therapy, Lymphoid leukemia, Loncastuximab tesirine, Scleroderma, CRS, JW, IND, Tafasitamab, Tisagenlecleucel, B-cell lymphoma, Patient, Systemic scleroderma, CD19, Blinatumomab, FDA, Lupus, Acute leukemia, SLE, Chronic lymphocytic leukemia, Novartis, Sjögren syndrome, Neurotoxicity, Quality of life, NHL, Fast Track, ALL, Cytokine release syndrome, CLL, Vaccine, Pharmaceutical industry, Amgen

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, FSE, EZH1, Annual general meeting, PST, Food, JAK, ASH, Patient, ARID1A, FDA, Abstract, EST, Society, Ruxolitinib, EZH2, Fast Track, BET, Pharmaceutical industry, Video game, Tafasitamab, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
  • “Sales of Monjuvi remain on track for its approved indication, allowing us to narrow our full-year 2023 guidance target.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Annual general meeting, Food, Fast Track, Ruxolitinib, Conference call, BET, FSE, EZH2, CET, EZH1, JAK, Society, FDA, ASH, Abstract, PST, Patient, Conference, Webcast, ARID1A, Pharmaceutical industry, Cryptocurrency, Video game, Tafasitamab, MorphoSys

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points: 
  • “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
  • Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.